| Title |
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|
|---|---|
| Published in |
Lancet Oncology, June 2017
|
| DOI | 10.1016/s1470-2045(17)30421-7 |
| Pubmed ID | |
| Authors |
Kevin J Harrington, Robert L Ferris, George Blumenschein, A Dimitrios Colevas, Jérôme Fayette, Lisa Licitra, Stefan Kasper, Caroline Even, Everett E Vokes, Francis Worden, Nabil F Saba, Naomi Kiyota, Robert Haddad, Makoto Tahara, Viktor Grünwald, James W Shaw, Manish Monga, Mark Lynch, Fiona Taylor, Michael DeRosa, Laura Morrissey, Kim Cocks, Maura L Gillison, Joël Guigay |
X Demographics
The data shown below were collected from the profiles of 38 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 16% |
| Spain | 6 | 16% |
| United Kingdom | 5 | 13% |
| France | 2 | 5% |
| Australia | 1 | 3% |
| Chile | 1 | 3% |
| New Zealand | 1 | 3% |
| Ecuador | 1 | 3% |
| Unknown | 15 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 27 | 71% |
| Practitioners (doctors, other healthcare professionals) | 6 | 16% |
| Scientists | 4 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 298 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 298 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 46 | 15% |
| Other | 32 | 11% |
| Student > Ph. D. Student | 26 | 9% |
| Student > Master | 24 | 8% |
| Student > Doctoral Student | 19 | 6% |
| Other | 57 | 19% |
| Unknown | 94 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 102 | 34% |
| Biochemistry, Genetics and Molecular Biology | 24 | 8% |
| Nursing and Health Professions | 17 | 6% |
| Agricultural and Biological Sciences | 15 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 3% |
| Other | 25 | 8% |
| Unknown | 107 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 100. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2023.
All research outputs
#431,982
of 26,017,215 outputs
Outputs from Lancet Oncology
#550
of 6,958 outputs
Outputs of similar age
#9,115
of 333,328 outputs
Outputs of similar age from Lancet Oncology
#13
of 147 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,328 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.